文献速递肿瘤 PET/CT

[18F]FDG PET/CT 在肺癌治疗反应监测中的作用

The Role of [18F]FDG PET/CT in Monitoring of Therapy Response in Lung Cancer.
PubMed 文献 · Semin Nucl Med · 2025-02-27

本文综述 [18F]FDG PET/CT 在肺癌(尤其非小细胞肺癌)治疗反应评估中的核心作用,讨论传统疗效标准及其在免疫治疗时代的调整,强调代谢影像与既定标准整合的价值,并探讨非 [18F]FDG 示踪剂与影像组学的应用前景。

要点

  • [18F]FDG PET/CT 凭借评估代谢活性的能力,已成为肺癌管理多个阶段的标准诊疗手段。
  • 综述检视传统疗效标准及其在免疫治疗时代的调整,强调代谢影像与既定标准整合以改善治疗评估。
  • 靶向不同生物学通路的非 [18F]FDG PET 示踪剂与影像组学在疗效评估中的价值受到关注。

核心结论

  • 尽管多种代谢反应标准在常规临床应用中存在挑战,[18F]FDG PET/CT 仍是监测肺癌治疗反应的关键工具。

研究设计与样本

  • 本文为综述,聚焦 [18F]FDG PET/CT 在肺癌治疗反应评估中的作用,尤其关注非小细胞肺癌(NSCLC)。

主要发现

  • 肺癌仍是全球癌症死亡的主要原因之一,全分期 5 年相对生存率低于 30%。
  • 肺癌有多种可用的治疗策略并持续演变,治疗主要根据疾病类型和分期制定。
  • 准确监测治疗反应对优化治疗结局至关重要。
  • [18F]FDG PET/CT 因能评估代谢活性,已成为肺癌管理多个阶段的标准诊疗手段。
  • 综述探讨了靶向不同生物学通路的非 [18F]FDG PET 示踪剂在深入理解肿瘤生物学、治疗反应和预测结局方面的潜力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer remains a leading cause of cancer deaths worldwide, with an all stage 5-year relative survival rate of less than 30%. Multiple treatment strategies are available and continue to evolve, with therapy primarily tailored to the type and stage of the disease. Accurate monitoring of therapy response is crucial for optimizing treatment outcomes. PET/CT imaging with [18F]FDG has become the standard of care across various phases of lung cancer management due to its ability to assess metabolic activity. This review underscores the pivotal role of [18F]FDG PET/CT in evaluating therapy response in lung cancer, particularly in non-small cell lung cancer (NSCLC). It examines conventional response criteria and their adaptations in the era of immunotherapy, highlighting the value of integrating metabolic imaging with established criteria to improve treatment assessment and guide clinical decisions. The potential of non-[18F]FDG PET tracers targeting diverse biological pathways to provide deeper insights into tumor biology, therapy response and predictive outcomes is also explored. Additionally, the emerging role of radiomics in enhancing treatment efficacy assessment and improving patient management is briefly highlighted. Despite the challenges in the routine clinical application of various metabolic response criteria, [18F]FDG PET/CT remains a crucial tool in monitoring therapy response in lung cancer. Ongoing advancements in therapeutic strategies, radiopharmaceuticals, and imaging techniques continue to drive progress in lung cancer management, promising improved patient outcomes.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ayeni A, Evbuomwan O, Vangu MW, et al. The Role of [18F]FDG PET/CT in Monitoring of Therapy Response in Lung Cancer. Semin Nucl Med. 2025. PMID: 40021362. doi:10.1053/j.semnuclmed.2025.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。